Treatment Advances in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer

Neal Shore, MD, FACS, provides an overview of BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC), with a focus on patient presentation and risk stratification.

An expert urologist reviews the clinical hallmarks of high-risk BCG-unresponsive NMIBC and discusses the unmet needs and treatment goals.

Following a review of the limitations of current treatment options, Neal Shore, MD, MFACS, discusses the SunRISe-1 trial investigating TAR-200 plus cetrelimab in patients with high-risk NMIBC.

Neal Shore, MD, FACS, reviews agents and treatment options being researched in the BCG-unresponsive NMIBC treatment space.

Comprehensive insights on the unmet needs addressed by TAR-200 in BCG-unresponsive non-muscle-invasive bladder cancer.

A urologist discusses treatments in the pipeline that can further improve the therapeutic landscape in BCG-unresponsive NMIBC.

Neal Shore, MD, FACS, offers clinical insights on optimizing patient selection and treatment sequencing in BCG-unresponsive NMIBC.